Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus rating of “Buy” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $89.90.

A number of equities analysts have recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. HC Wainwright lifted their price target on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners raised their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Stifel Nicolaus boosted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd.

Janux Therapeutics Trading Up 0.5 %

Shares of NASDAQ JANX opened at $40.91 on Wednesday. The firm has a market capitalization of $2.15 billion, a PE ratio of -34.97 and a beta of 3.23. Janux Therapeutics has a one year low of $7.79 and a one year high of $71.71. The business has a 50-day moving average price of $52.59 and a two-hundred day moving average price of $48.43.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue was down 82.6% compared to the same quarter last year. Research analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. This trade represents a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,334 shares of company stock worth $6,070,020 over the last ninety days. Company insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in JANX. Amalgamated Bank grew its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $139,000. Finally, AQR Capital Management LLC acquired a new position in shares of Janux Therapeutics in the second quarter valued at $215,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.